Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
Takeda
Masayuki
M
Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan.
Okamoto
Isamu
I
Fukuoka
Masahiro
M
Nakagawa
Kazuhiko
K
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib